Home :: Parkinson & Alzheimer :: Brands
RXHEALTHDRUGS
 |
|
 |
|
 Actual product may differ in
appearance from image shown. |
Bromocriptin (Bromocriptine)
Description
Bromocriptineinhibits the secretion of the hormone prolactin from the pituitary gland. It also mimics the action of dopamine, a chemical lacking in the brain of someone with Parkinson's disease.
|
|
|
 |
|
 |
|
|
|
|
 Actual product may differ in
appearance from image shown. |
Eldepryl (Selegiline)
Synonyms: Selegin, Selgin, Carbex, Jumex, L-Deprenalin, Sd Deprenyl, Selegilina
Description
ELDEPRYL (selegiline hydrochloride) is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl. The chemical name is: (R)-(-)-N,2-dimethyl-N-2-propynylphenethylamine hydrochloride. It is a white to near white crystalline powder, freely soluble in water, chloroform, and methanol.
Selegiline prevents the breakdown of a chemical in the brain called dopamine. Low levels of this chemical are associated with Parkinson's disease.
Selegiline is used together with other medicines to treat symptoms of Parkinson's disease.
|
|
|
|
|
|
|
|
|
|
 Actual product may differ in
appearance from image shown. |
Parlodel (Bromocriptine)
Description
Parlodel inhibits the secretion of the hormone prolactin from the pituitary gland. It also mimics the action of dopamine, a chemical lacking in the brain of someone with Parkinsonis disease
|
|
|
|
|
|
|
|
|
|
 Actual product may differ in
appearance from image shown. |
Requip (Ropinirole)
Description
REQUIP (ropinirole hydrochloride) is an orally administered non-ergoline dopamine agonist. It is the hydrochloride salt of 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one monohydrochloride and has an empirical formula of C16H24N2O
•HCl. The molecular weight is 296.84 (260.38 as the free base).
Requip is not a cure for Parkinson's disease. However, it does alleviate symptoms of the disease, and it can shorten the "off" periods of immobility that patients on long-term levodopa therapy often begin to experience
|
|
|
|
|
|
|
